Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person CYLD is an ovarian tumor (OTU) domain-containing deubiquitin...
| Class:Id | Summation:936430 |
|---|---|
| _displayName | CYLD is an ovarian tumor (OTU) domain-containing deubiquitin... |
| _timestamp | 2016-05-04 15:49:54 |
| created | [InstanceEdit:936409] Garapati, P V, 2010-08-22 |
| literatureReference | [LiteratureReference:936403] The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response [LiteratureReference:936442] Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD |
| modified | [InstanceEdit:8869459] Jupe, Steve, 2016-05-04 |
| text | CYLD is an ovarian tumor (OTU) domain-containing deubiquitinating enzyme (DUB) and has been identified as a negative regulator of DDX58 (RIG-I) mediated antiviral signaling. CYLD associates with the CARD domain of DDX58 and removes K63-linked ubiquitin from the DDX58 CARDs that are conjugated by the E3 ubiquitin ligase, TRIM25 and RNF135. |
| (summation) | [BlackBoxEvent:936390] CYLD mediated deubiquitination of DDX58 (RIG-I) [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by CYLD is an ovarian tumor (OTU) domain-containing deubiquitin... (936430)
